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A review of the pharmacological and therapeutic effects of auraptene 1 
Abstract: 2 
There is a growing awareness in herbal medicine globally, as they are usually safe and devoid of 3 
significant adverse effects. Auraptene is a natural bioactive monoterpene coumarin ether and is 4 
consumed all over the world. There is growing evidence of the therapeutic benefits of auraptene. 5 
Auraptene, also known as aurapten and 7-geranyloxycoumarin, is a bioactive monoterpene 6 
coumarin from Rutaceae family, which is isolated from Citrus aurantium (Seville orange) and bael 7 
fruit (Aegle marmelos). Auraptene is a highly pleiotropic molecule which can modulate 8 
intracellular signaling pathways that control inflammation, cell growth and apoptosis. It potentially 9 
has a therapeutic role in the prevention and treatment of various diseases due to its anti-10 
inflammatory and antioxidant activities as well as its excellent safety profile. In the present article, 11 
various pharmacological and therapeutic effects of auraptene were reviewed. Different online 12 
databases using keywords such as auraptene, therapeutic effects and pharmacological effects were 13 
searched until the end of September 2018 for this purpose. Auraptene has been suggested to be 14 
effective in the treatment of a broad range of disorders including inflammatory disorders, 15 
dysentery, wounds, scars, keloids and pain. In addition, different studies have demonstrated that 16 
auraptene possesses numerous pharmacological properties including anti-inflammatory, anti-17 
oxidative, anti-diabetic, anti-hypertensive and anti-cancer as well as neuroprotective effects. The 18 
present review provides a detailed survey of scientific researches regarding pharmacological 19 
properties and therapeutic effects of auraptene. 20 
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1. Introduction: 24 
Herbal compounds are excellent candidates for finding new therapeutic options for the 25 
management of various diseases. Auraptene, also known as 7-geranyloxycoumarin, is a 26 
prenyloxycoumarin found in plants belonging to Apiacea and Rutaceae families (1). Different 27 
pharmacological and medicinal properties have been described for auraptene including anti-28 
diabetic (2), antiprotozoal (3), anti-genotoxic (4), anti-inflammatory (5) and immunomodulatory 29 
(6) activities. Auraptene has been shown to have a significant effect on the prevention and 30 
treatment of various chronic diseases such as cystic fibrosis, nonalcoholic fatty liver and 31 
hypertension (7). 32 
Dietary administration of auraptene had cancer chemo-preventive effects in animal models of oral 33 
(8), breast (9), prostate (10), colon (11) and esophagus (12) cancers. The possible mechanism for 34 
these effects could be due to its glutathione S transferase inducing activity (13), lipid peroxidation 35 
(14), inhibition of key biological targets such as metalloproteinases (MMPs), glycoprotein P, 36 
peroxisome proliferator-activated receptors (PPARs), acetylcholinesterase (15) modulation of 37 
inflammation (16), suppression of superoxide generation (17), inhibition of microglial activation 38 
and inflammatory mediators (18). This article aims to review the effects of auraptene in the 39 
prevention and management of various conditions.   40 
1.1.Structural description, bioavailability, and safety of auraptene: 41 
Auraptene is a member of the class of coumarins that is umbelliferone in which the phenolic 42 
hydrogen has been replaced by a geranyl group (Figure 1). It is isolated from several edible fruits 43 
and vegetables and exhibits a variety of therapeutic properties. Auraptene can be prepared with a 44 
reaction between 7-hydroxycoumarin and geranyl bromide in K2CO3 solution (19). Auraptene can 45 
also be synthesized from umbelliferone by prenylation with NaH and geranyl bromide in 46 
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dimethylformamide (DMF) (20). Auraptene can also be synthesized from 7-hydroxycoumarin 47 
under alkaline conditions (DBU) using nuclear magnetic resonance (NMR) spectroscopic methods 48 
including nuclear magnetic resonance spectroscopy (21). 49 
When the acute and subacute toxicity of orally administrated auraptene in rats was investigated, 50 
varying concentrations of auraptene (125, 250, 500, 1000 and 2000 mg/kg body weight) had no 51 
effect on mortality for a period of two days. However, administration of auraptene for 28 days 52 
showed some differences in the hematological and biochemical parameters of the treated and 53 
untreated groups, but all differences were within normal reference ranges. Histopathological 54 
investigation showed no toxic effects suggesting that suggested that auraptene is safe (22). 55 
2. Methods:  56 
We searched the literature available in ISI Web of Knowledge, Medline, Pub Med, Scopus and 57 
Google Scholar databases for English articles published until September 2018. For this purpose, 58 
we used appropriate keywords including auraptene, anticancer, anti-inflammatory, 59 
cardioprotective, immunomodulation, anti-diabetic, and neuroprotective. Sixty-five studies were 60 
considered eligible for inclusion in this review. Abstracts or unpublished articles and non-English 61 
language articles were excluded. 62 
3. Results: 63 
 64 
3.1. Auraptene and cancer: 65 
Cancer has high mortality and morbidity worldwide. There are a number of unwanted side effects 66 
which occur during chemotherapy and radiotherapy. Natural therapies, including the use of plant-67 
derived compounds, potentially have a better safety profile (23). When the antiangiogenic activity 68 
of auraptene was investigated in vitro, auraptene (0-500 nM) dose-dependently inhibited vascular 69 
4 
 
endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) tube 70 
formation, viability, migration and invasion of endothelial cells (24).  71 
Effect of auraptene (0-100 µM) in human gastric cancer cells (SNU-1 cell line) showed that 72 
auraptene increased the sub-G1 phase cells and fragmented nuclei. It also induced depolarization 73 
of the mitochondrial membrane and regulated apoptotic signaling by downregulating the 74 
mammalian target of rapamycin (mTOR) pathway via Akt (protein kinase B) pathway (25).  75 
The synergic effects of auraptene on anticancer drugs (cisplatin, paclitaxel, and 5-fluorouracil (5-76 
FU)) were studied on esophageal carcinoma cells (KYSE30 cell line). Auraptene enhanced the 77 
cytotoxicity of cisplatin, paclitaxel and 5-FU, as well as the apoptosis induced by anticancer 78 
agents. Auraptene also down-regulated the expression of the cancer stem cell markers (12).  79 
The effect of auraptene was investigated on the growth capacity of cervical cancer cells and 80 
ovarian cancer cells. Results revealed that auraptene reduced cell viability and inhibited in vitro 81 
migration and invasion, as well as suppressed matrix metalloproteinase (MMP)-2 and MMP-9 82 
enzymatic activity (26). Combinatorial treatment with hyperthermia and auraptene in human colon 83 
adenocarcinoma cells resulted in reduced cell viability and up-regulation of P21 expression 84 
compared to untreated cells (11).  85 
The effects of auraptene on beta-catenin-T-cell factor (TCF) activity as well as cell cycle 86 
expression levels of beta-catenin target genes such as c-myc (a human gene over-expressed in 87 
various cancers) were evaluated in human colorectal cancer cells. Treatment with auraptene for 88 
48h inhibited cell growth with G2/M arrest in both caco-2 and DLD-1 cell lines. Auraptene 89 
suppressed beta-catenin/TCF activity in caco-2 and enhanced its activity in DLD-1. The 90 
modulation of beta-catenin/TCF activity by auraptene was inversely correlated with c-myc 91 
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expression levels. This suggests that auraptene induced inhibition of growth in these cells by 92 
different mechanisms independent on the modulation of beta-catenin-TCF signaling (27).  93 
The effect of auraptene on the growth and sphere (surrogate tumors) formation of HT-29 94 
(colorectal adenocarcinoma) wild type and FOLFOX (a combination chemotherapy regimen that 95 
is used to treat colorectal cancer)-resistant and HT-116 (colorectal carcinoma) wild type and 96 
FOLFOX-resistant were studied. Auraptene significantly inhibited the growth of parental and 97 
FOLFOX-resistant lines in both types of cells. (28).  98 
Antitumor activity of auraptene was studied against intraperitoneally transplanted azoxymethane 99 
(AOM) in mice.  Oral administration of (0.01 and 0.05%) of auraptene for 17 weeks significantly 100 
reduced the incidences of colorectal adenocarcinomas, the multiplicity of colon adenocarcinomas 101 
and colonic inflammation scores as well as increased the apoptotic index in colonic malignancies 102 
(29).  In another study, where the preventive effect of auraptene (250 ppm) in the diet for 10 weeks 103 
on AOM induced colorectal preneoplastic lesions in mice was examined, auraptene significantly 104 
reduced the number of aberrant crypt foci, ß-catenin-accumulated crypt, cell proliferation activity 105 
but increased apoptotic cells (30). Similarly, administration of auraptene in the diet for 15 weeks 106 
on colon carcinogenesis model induced by AOM/dextran sodium sulfate (DSS) in mice showed 107 
auraptene suppressed the development of colonic adenocarcinomas. There was a reduction in 108 
PCNA-labeling index and survivin-positive rate and increased terminal deoxynucleotidyl 109 
transferase dUTP nick end labeling (TUNEL)-positive rate in colonic adenocarcinomas. 110 
Additionally, auraptene reduced the incidence of colonic adenomas, total colonic tumors and 111 
expression of pro-inflammatory cytokines. This suggests that auraptene inhibited colitis-related 112 
colon carcinogenesis by modulating inflammation in mice (31).  113 
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In another study the effect of auraptene (500 ppm) in the diet for 20 weeks on NMBA-induced 114 
esophageal tumorigenesis in the rat was examined. Auraptene significantly reduced the incidence 115 
and the frequency of tumors as well as the incidence of severe dysplasia.  This might be mediated 116 
by suppression of cell proliferation in the esophageal epithelium (32).  117 
Auraptene has shown to significantly reduce extracellular signaling-regulated kinase (ERK) 1/2 118 
activation, H. pylori adhesion and IL-8 production in human gastric carcinoma cell lines. In 119 
addition, the knockdown of CD74 expression led to significant reduction of H. pylori adhesion but 120 
elevated IL-8 production suggesting this effect is potentially mediated by disrupting ERK1/2 (33).  121 
The effect of administration of auraptene in the diet for 7 weeks on liver carcinogenesis model 122 
induced by N, N-diethylnitrosamine (DEN) in the rat was evaluated. Auraptene inhibited the 123 
incidence of liver cell carcinoma and cell proliferation in liver cell neoplasms models (34).  In a 124 
similar study of auraptene on DEN-induced hepatocarcinogenesis cells showed auraptene 125 
suppressed the occurrence of mutations in the beta-catenin gene in liver cell adenomas probably 126 
by negative selection of mutation harboring neoplastic cells (35).  127 
The effect of auraptene was investigated on the cell cycle and the genes related to the cell cycle in 128 
mammary adenocarcinoma (MCF-7) cells line. Auraptene significantly reduced cyclin D1 protein 129 
expression in these cell lines, inhibited IGF-1 stimulated S phase of cell cycle and modulated the 130 
transcription of various genes involved in the cell cycle (9).  131 
Tang et al. examined the in vivo effects of auraptene (500 ppm) in the diet for 15 weeks on prostate 132 
carcinogenesis using transgenic rats with adenocarcinoma of the prostate. Auraptene significantly 133 
reduced the epithelial component and high-grade lesions in the prostate.  Furthermore, they 134 
examined the chemotherapeutic effects of auraptene using human prostate cancer cells in vitro. 135 
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Auraptene significantly reduced the cell viability in a dose-dependent manner and increased 136 
apoptosis in these cell lines (10).  137 
Effect of auraptene (100 and 500 ppm) in the diet for 38 weeks on AOM induced colon 138 
carcinogenesis in the rat was examined. Dietary administration of auraptene significantly reduced 139 
the incidence and multiplicity of colon adenocarcinoma and the production of aldehydic lipid 140 
peroxidation products in the colonic mucosa. Auraptene suppressed the expression of cell 141 
proliferation biomarkers in the colonic mucosa. It also increased the activities of phase II drug-142 
metabolizing enzymes in the liver and colon. The protective effects of auraptene in the AOM 143 
model of colon carcinogenesis have been suggested to be related to its ability to suppress cell 144 
proliferation and lipid peroxidation (14). Similarly, administration of auraptene in the diet after 145 
induction of pulmonary metastasis in mice for 2 weeks reduced the numbers of metastatic lung 146 
tumors, cross-sectional areas and volumes of the tumors and increased the apoptotic indices 147 
compared to the controls (36).  148 
The preventive effect of auraptene in the diet on N-methylnitrosourea (MNU)-induced mammary 149 
carcinogenesis model in the rat showed auraptene inhibited cell proliferation and reduced the 150 
expression of cyclin D1, c-Myc, and ODC in the tumors (37). The effect of auraptene was 151 
investigated on cell proliferation in the human breast carcinoma cell line (MCF-7 and MDA-MB-152 
231). It showed auraptene significantly suppressed the proliferation in both the cell lines and 153 
reduced insulin-like growth factor1 (IGF-1)-induced cyclin D1 expression in MCF-7 cells. In 154 
addition, the in vivo effects of auraptene in the diet on MNU-induced mammary carcinogenesis in 155 
the rat showed that auraptene delayed median time to the tumor, reduced incidence of tumor and 156 
cyclin D1 expression (38).  157 
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Dietary administration of auraptene after induction of oral carcinogenesis in the rat for 22 weeks 158 
significantly reduced the frequency and incidences of tongue cancer, 5-bromodeoxyuridine 159 
(BrdU)-labelling index and polyamine concentrations in the oral mucosa. It also increased the 160 
activities of GST and QR in the tongue which suggests that the mechanism for this action might 161 
be related to the suppression of cell proliferation (8).  162 
Antitumor activity of auraptene was studied on the prostate cancer cells (PC3 and DU145 cell 163 
line). After 24 h, auraptene significantly exhibited a cytotoxic effect in a time-dependent manner 164 
and increased the number of TUNEL-positive cells in a dose-dependent manner. Auraptene 165 
activated caspase-9, caspase-3 and pro-apoptotic protein Bax. It also suppressed the expression of 166 
anti-apoptotic proteins including Bcl-2 and myeloid cell leukemia 1 (Mcl-1) in these prostate 167 
cancer cells. The possible mechanism of chemo-preventive effects of auraptene could be related 168 
to Mcl-1-mediated activation of caspases (39).  169 
The effect of auraptene was investigated on human renal cancer cells (RCC4 and RCC4/VHL cell 170 
lines). Results indicated that auraptene inhibited glycolytic and mitochondrial metabolism as well 171 
as VEGF and tube formation by HUVECs. It also decreased cell motility, induced hypoxia-172 
inducible factor 1α (HIF-1α) degradation in a von hippel–lindau (VHL)-independent manner and 173 
promoted HIF-1a protein degradation by inhibition of translation initiation (40).  174 
Topical administration of auraptene (16 nmol and 160 nmol/o.1 ml in acetone) after induction of 175 
skin tumor by 12-O-tetradecanoylphorbol-13-acetate (TPA) in the rat twice a week for 20 weeks 176 
significantly reduced the incidence and number of tumors (17). Comparison of the cytotoxicity of 177 
auraptene and umbelliprenin against some cancerous cell lines such as HeLa (cervical cancer cell 178 
line), Jurkat (T cell leukemia cell line), MCF-7 (breast cancer cell line) and KYSE-30 (oesophageal 179 
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carcinoma cell line) showed that auraptene is more cytotoxic than umbelliprenin (41). The 180 
anticancer effects of auraptene are summarized in Table 1. 181 
3.2. Auraptene and the nervous system: 182 
The effect of auraptene (6.0 mg/day, p.o.) on cognition was studied in healthy volunteers. 183 
Cognitive assessments were evaluated using mild cognitive impairment (MCI) screen and mini-184 
mental state examination (MMSE) at baseline and at 24 weeks. Results showed that auraptene did 185 
not improve cognitive function after 24 weeks compared to baseline (42). 186 
The effect of auraptene (10 and 25 mg/kg/day, s.c.) was evaluated 5 days before and 3 days after 187 
the induction bilateral common carotid artery occlusion in mice. The results indicated that 188 
auraptene decreased the numbers of ionized calcium binding adaptor molecule 1 positive cells, 189 
glial fibrillary acidic protein positive cells and COX-2-positive cells. The presence of auraptene in 190 
the brains of mice following (50 mg/kg, i.p.) administration of auraptene suggests that it has the 191 
ability to pass through the blood-brain barrier. Results of in vitro study using cultured astrocytes 192 
showed that auraptene suppressed the mRNA expression of the inflammatory cytokines (43). 193 
Similarly, the effect of administration of auraptene on bilateral common carotid artery occlusion 194 
induced cerebral global ischemia in mice showed that auraptene suppressed neuronal loss in the 195 
hippocampal regions of CA1, CA2 and CA3, microglia activation by reduction IBA1-positive cells 196 
in the hippocampus and COX-2 expression in astrocytes (16). Administration of auraptene intra-197 
peritoneally after induction of demyelination by cuprizone for 21 days increased the 198 
immunoreactivity to oligodendrocyte transcription factor 2 (olig2) which is a marker of precursor 199 
cells of oligodendrocytes and the number oligodendrocyte lineage precursor cells (OPCs). There 200 
was also a reduction in microglial activation (44). 201 
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The neuroprotective and memory enhancing effects of auraptene (4, 8 and 25 mg/kg, p.o.) were 202 
investigated in bilateral carotid artery occlusion model of cerebral global ischemia. The results 203 
showed that auraptene significantly reduced the scape latency time and increased the percentage 204 
of time spent and traveled pathway in the target quadrant in the Morris water maze. Auraptene also 205 
reduced the MDA concentrations and increased glutathione (GSH) content in the cortex as well as 206 
in the hippocampus. Histopathological data showed that auraptene protected cerebrocortical and 207 
hippocampus neurons against ischemia (45). In the the rat pheochromocytoma cell line (PC12 208 
cells), which is a model system for studies on neuronal proliferation and differentiation, auraptene 209 
induced activation of the extracellular signal-regulated kinases (ERK)1/2. In addition, auraptene 210 
promoted neural outgrowth from PC12 cells (46). 211 
The effect of auraptene on the cognitive performance induced by scopolamine showed that 212 
auraptene significantly reversed scopolamine-induced avoidance memory retention  impairments, 213 
24 and 168 hr after training trial in step-through task (47). The neuroprotective effects of auraptene 214 
are summarized in Table 2. 215 
3.3. Auraptene and the cardiovascular system: 216 
The effect of auraptene (5 and 50 mg/kg, orally) once daily for 6 weeks on myocardial infarction 217 
(MI) in rats showed improved left ventricular fractional shortening (LVFS) and reduced posterior 218 
wall thickness (PWT), myocardial cell diameter and perivascular fibrosis. In addition, auraptene 219 
inhibited the activations of atrial natriuretic factor and MCP-1 mRNA levels (48).  220 
When auraptene was administered intraperitoneally in normotensive and desoxycorticosterone 221 
acetate (DOCA)-induced hypertensive rats, there was a significant reduction in mean systolic 222 
blood pressure in both groups in a dose and time-dependent manner. This suggests that auraptene 223 
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had anti-hypertensive properties and dietary supplementation with auraptene would be a 224 
potentially beneficial strategy for the management of hypertension (49).  225 
The influence of auraptene on mean arterial blood pressure and heart rate was studied in the rat. 226 
Animals were divided to a control group that received single intravenous injections of normal 227 
saline/DMSO, auraptene and nifedipine as a positive control.  Although auraptene did not have 228 
any significant effect on heart rate, it significantly reduced mean arterial blood pressure. This 229 
suggests a potential antihypertensive effect of auraptene comparable to established anti-230 
hypertensives such as nifedipine at the used concentrations (50). Auraptene is also potent in vitro 231 
inhibitor of the spontaneous beating of mouse myocardial cells. The IC50 of auraptene was 0.6 232 
µg/ml, which is comparable to that of verapamil, a well-known Ca+2 antagonist (51). The 233 
cardioprotective effects of auraptene are summarized in Table 3. 234 
3.5. Auraptene and the immune system: 235 
Auraptene significantly increased the expressions of IL-10, IFN-γ, IFNγ/IL-4 and IL-10/IL-4 ratio 236 
in non-phytohaemagglutinin (PHA)-stimulated lymphocytes. After PHA stimulation auraptene 237 
significantly reduced the expressions of IL-4, IL-10, IFN-γ, NF-κB and NO and increased IFN-238 
γ/IL-4 and IL-10/IL-4 ratio. This suggests the effects of auraptene on T cell subsets shifting 239 
towards Th1 (IFN-γ) and Treg (IL-10) may play a therapeutic role in the management of Th2 cells 240 
predominant conditions (52). 241 
The effect of auraptene was evaluated on DNA damage in human peripheral lymphocytes induced 242 
by H2O2. This demonstrated that auraptene significantly reduced the genotoxicity of H2O2. This is 243 
most probably due to the prenyl moiety and suppression of superoxide anion (O2-) generation (4). 244 
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The effect of oral administration of auraptene on macrophage and lymphocyte functions in mice 245 
showed that auraptene significantly increased glucose consumption of peritoneal macrophages, 246 
activities of acid phosphatase and beta-glucuronidase as well as the production of IL-1β and TNF-247 
α (6). Studies on the effect of auraptene on T lymphocyte activation using mice CD3/CD28-248 
activated lymphocytes showed that auraptene inhibits the CD3/CD28-activated lymphocyte 249 
proliferation by inhibition of cell cycle progression and cell division. Furthermore, auraptene 250 
reduced the T cell cytokines (53). The immunomodulatory effects of auraptene are summarized in 251 
Table 4. 252 
3.5. Auraptene and gastrointestinal system: 253 
The beneficial effect of auraptene on the lithocholic acid (LCA)-induced cholestatic liver injury 254 
was investigated in mice. Different concentrations of auraptene were administered orally once a 255 
day for 7 days to mice. Auraptene promoted bile acid efflux from the liver into the intestine via 256 
induction of farnesoid X receptor (FXR) target genes canalicular bile salt export pump (Bsep) and 257 
multidrug resistance-associated protein 2 (Mrp2) expression. It also promoted liver repair through 258 
induction in the liver regeneration-related gene. It reduced hepatic uptake through inhibition in 259 
Na+/taurocholate cotransporting polypeptide (Ntcp) as well as suppressed the liver inflammation 260 
through repressing inflammation-related genes. Auraptene reduced bile acid synthesis through 261 
repressing FXR-target genes cholesterol 7a-hydroxylase (Cyp7a1) and oxysterol 12a-hydroxylase 262 
(Cyp8b1) and increased bile acid metabolism through induction of sulfotransferase 2a1 (Sult2a1) 263 
(54).  264 
The effect of auraptene was investigated on azoxymethane (AOM)-induced colonic aberrant crypt 265 
foci (ACF) in the male albino mice. Dietary administration of auraptene significantly reduced the 266 
frequency of ACF in a dose-dependent manner and suppressed the expression of cell proliferation 267 
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biomarkers and increased the activities of phase II enzymes (GST and QR) in the liver and colon. 268 
This suggests that the protective effects of auraptene may be related to enhancement in phase II 269 
enzymes activity in the liver and colon as well as suppression of cell proliferation in the colonic 270 
mucosa (13). 271 
The effect of auraptene in H. pylori–infected mice using a feeding needle showed that auraptene 272 
inhibited H. pylori colonization and resultant gastric mucosal injuries, attenuated expressions of 273 
CD74, IL-1β, TNF-α in stomach tissue and level of macrophage inhibitory protein-2 (MIP-2) in 274 
the serum (55). In vivo effects of auraptene in the diet on hepatic lipid metabolism using Otsuka 275 
Long-Evans Tokushima fatty rats showed that auraptene reduced abdominal white adipose tissue 276 
weight and hepatic triglyceride levels. It also increased the activities of carnitine 277 
palmitoyltransferase and peroxisomal ß-oxidation and expression of acyl-CoA oxidase in a dose-278 
dependent manner in the liver  (56). 279 
Kawada et al., showed that auraptene acts as an agonist of the isoforms peroxisome proliferator-280 
activated receptors (PPAR)α and PPARγ. At a concentration of 50 µM, auraptene activated PPARα 281 
and PPARγ while no effects were recorded for PPAR δ. Furthermore, auraptene was also able to 282 
enhance the mRNA expression level of adiponectin in 3T3-L1 adipocytes as well as the secretion 283 
of adiponectin (57). 284 
The effect of auraptene on thioacetamide (TAA)-induced hepatic fibrosis in mice showed a 285 
reduction of liver collagen content.   Auraptene also inhibited the activation of hepatic stellate cells 286 
by down-regulating the expression of transforming growth factor-ß1 (TGF-β1) and α-smooth 287 
muscle actin (α-SMA). There was also a reduction in the expression of NF-κB, TNF-α and IL-1β 288 
suggesting potential anti-inflammatory effects.   However,  the  changes in  these genes  and protein 289 
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expression, as  well as  ameliorative liver histology induced by auraptene were repealed by 290 
farnesoid X receptor  (FXR) antagonist guggulsterone (a phytosteroid found in the resin of the 291 
guggul plant, Commiphora mukul) in vivo and FXR siRNA in vitro (58).  292 
Auraptene when administered through the diet significantly reduced H. pylori colonization in H. 293 
pylori–infected mongolian gerbil but did not have an effect on gastric inflammation (59). 294 
Administration of auraptene (0.1% w/w, in diet) after induction of ulcerative colitis by DSS model 295 
in mice inhibited the gelatinolytic activity of MMP-7 as well as the expression of MMP-2 and 296 
MMP-9 in the mucosa of the colon (60). The protective effects of auraptene on gastrointestinal 297 
diseases are summarized in Table 5. 298 
3.6. Miscellaneous effects of auraptene: 299 
Auraptene (0.1 and 0.2%, in diet) significantly reduced lipid accumulation in the liver and skeletal 300 
muscle and increased the mRNA expression of the PPARα target genes such as fatty acid 301 
translocase (FAT)/CD36, acyl-CoA synthetase (ACS), acyl-CoA oxidase (ACO) and carnitine 302 
palmitoyl transferase 1 (CPT1) involved in fatty acid oxidation in high-fat-diet (HFD)-fed KK-Ay 303 
diabetic obese mice (2). The therapeutic potential of auraptene was studied in a mice model of 304 
diabetes which was induced by streptozotocin. Results indicated that auraptene suppressed 305 
astroglial activation and the hyperphosphorylation of tau at 231 of threonine in neurons. It also 306 
recovered the suppression of neurogenesis in the dentate gyrus of the hippocampus in the 307 
hyperglycemic mice. The potential protective effects of auraptene could be associated with its anti-308 
inflammatory and anti-oxidative action in the hyperglycemic brain (61).  309 
Marquis and his colleagues evaluated the effect of auraptene on Porphyromonas gingivalis (P. 310 
gingivalis). It showed that auraptene inhibited the adherence of P. gingivalis to oral epithelial cells 311 
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and reduced the secretion of cytokines and MMP by LPS-stimulated macrophages. It also inhibited 312 
MMP-9 activity (62). The effects of auraptene on the secretion of inflammatory mediators and 313 
chemokine by LPS-stimulated oral epithelial cells showed that auraptene reduced the secretion of 314 
MMP-2, IL-6, IL-8 and chemokine (C-C motif) ligand (CCL)-5 secreted by Aggregatibacter 315 
actinomycetemcomitans lipopolysaccharide-stimulated oral epithelial cells. Furthermore, the 316 
effect of auraptene as a wound healing agent was examined using a gingival fibroblast model. 317 
Auraptene improved wound closure by promoting cell migration (63).  318 
The effect of auraptene on lipopolysaccharide (LPS)-stimulated murine macrophage line (RAW 319 
264.7) showed that auraptene had better biocompatibility and lower cytotoxicity compared to 320 
aspirin. In addition, it significantly reduced the production of PGE2, levels of mRNA expression 321 
and protein of COX-2 (5). Auraptene significantly suppressed the expression of monocyte 322 
chemoattractant protein-1 (MCP-1), COX-2 and iNOS as well as TNF-α release from the RAW 323 
264.7 cell line (64, 65).  324 
Auraptene inhibits Ba+2, acetylcholine or histamine-induced contractions of smooth muscles in 325 
accordance with its spasmolytic activity. Studies of structure-activity relationship performed with 326 
synthetic analogs of auraptene suggest that the observed spasmolytic activity is closely associated 327 
with the presence of both the geranyl chain and the benzopyrone ring (66).  328 
The effect of auraptene on the growth and viability of Leishmania major (L. major) Friedlin cells 329 
showed auraptene (2, 5, 7, 10 and 15 µg/ml) significantly inhibited growth of L. major 330 
promastigotes at the used concentrations (3). The miscellaneous effects of auraptene are 331 




4.  Conclusions:  334 
There is growing evidence on the multiple health benefits of auraptene. Studies suggest that 335 
auraptene has potential therapeutic benefits in a wide range of conditions ranging from diabetes to 336 
cancer. These effects are mediated via a variety of mechanisms including anti-inflammatory, anti-337 
oxidant and anti-tumor activities through its regulatory impacts on various molecular targets.  338 
This review showed a wide spectrum of effects of auraptene on different disorders both in 339 
experimental and clinical studies (Figure 2). With respect to the effects in cancer, auraptene has 340 
chemo-preventive and inhibitory effects on all stages of tumorigenesis, growth and proliferation 341 
of cancer cell lines. In experimental studies, auraptene had inhibitory effects on the proliferation 342 
of several cancer cell lines, the formation of DNA adducts, an increase of glutathione S-transferase 343 
activity and reduction of the number of aberrant crypt foci (precursors of colon cancers).   344 
Auraptene showed improved effects on memory and behavioral deficits, motor incoordination and 345 
short-term memory as well as decreased cerebral infarct size. In cardiovascular system, auraptene 346 
treatment reduced high blood pressure, cardiac hypertrophy and vasodilation in experimental 347 
research. On the gastrointestinal system, auraptene reduced abdominal white adipose tissue weight 348 
as well as H. pylori colonization and resultant gastric mucosal injuries. It also increased the 349 
activities of carnitine palmitoyltransferase, phase II enzymes and peroxisomal ß-oxidation as well 350 
as expression of Acyl-CoA oxidase in the liver and colon.  351 
In experimental studies, auraptene caused a significant reduction on blood glucose levels and 352 
dietary glucose absorption, an increase of serum insulin levels and protection of pancreatic islets. 353 
In experimental models of periodontal disease, auraptene reduced the adherence of P. gingivalis 354 
to oral epithelial cells as well as the secretion of cytokines (IL-8 and TNF-α) and MMP. Auraptene 355 
also has anti-inflammatory effects as well as reduction of immunological markers such as IL-4 and 356 
IL-10 and an increase of IFN-γ in experimental studies. 357 
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Auraptene due to its ability to affect a wide range of molecular targets with an excellent safety 358 
profile could potentially be a potential candidate for the prevention and/or management of a 359 
number of diseases. A wide range of pharmacological effects was reported for auraptene in the 360 
published studies so far mainly in experimental studies. However, more clinical trials are needed 361 
regarding the effects of auraptene before it could be translated in clinical practice. 362 
 363 
 364 
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Figure Legend 369 
Figure 1. Chemical structures of umbelliprenin (a) and auraptene (b). 370 
 371 
 372 
  373 
(a) 374 
 375 
  376 
(b) 377 
Figure 2.  Various effects of auraptene.  378 
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Inhibited tube formation, viability, migration and invasion of 
cells 
Induced cell cycle arrest and apoptosis 
Inhibited the growth and formation of colonospheres 
Suppressed beta-catenin mutation 
Inhibited cell proliferation 
Inhibited glycolytic and mitochondrial metabolism 
Suppressed neuronal loss and microglia activation 
Reversed memory retention impairments 
Reduced the scape latency time  
Increased percentage time spent and traveled pathway in 
target quadrant 
Improved left ventricular fractional shortening  
Reduced posterior wall thickness myocardial cell diameter 
and perivascular fibrosis 
Reduced mean systolic blood pressure and mean arterial 
blood pressure 
Increased bile acid efflux into intestine from liver  
Reduced hepatic uptake, liver inflammation, bile acid 
synthesis 
Inhibited gastric mucosal injuries 
Reduced H. pylori colonization in glandular stomach lesions 
Increased glutathione S-transferase and quinone reductase 
activities 
Reduced IL-4, IL-10, IFN-γ, NF-κB  
Increased IFN-γ/IL-4 and IL-10/IL-4 ratio 
Inhibited CD3/CD28-activated lymphocyte proliferation 
Increased production of IL-1β and TNF-α 
Suppressed lipid accumulation 
Inhibited enhancement in plasma glucose and insulin levels 
Inhibited Porphyromonas gingivalis adherence to oral 
epithelial cells 
Reduced PGE2 production 
Suppressed the expression of MCP-1, COX-2 
Inhibited growth of Leishmania major promastigotes 
20 
 
Table 1. Summary of studies reporting anticancer effects of auraptene. 381 
Dose Exp. model Effect Ref. 
0-500 nM, In 
vitro 
 
VEGF-induced HUVEC growth 
stimulation                                                                                                                                                                                                                                                                                                                                                            
Inhibited tube formation, viability, migration 





Human gastric cancer cell line Induced cell cycle arrest and apoptosis in 
SNU-1 cells via activation of p53 and 
inhibition of mTOR signaling 
 
(25) 








25, 50, and 
100 μM, In 
vitro 
 
Human ovarian and cervical cancer cell 
line 
Inhibited migration and invasion capacity of 
human ovarian and cervical  and ovarian 
cancer by decreasing MMP-2, MMP-9 
activity 
(26) 




Human colon adenocarcinoma cell line Reduced cell viability  
Up regulated of P21 expression 
(11) 
75 μM, In 
vitro 
 
Human colorectal cancer cell line Induced growth inhibition (27) 
2.5, 5, 10, 20 
and 40 µM, 
In vitro 
 
Human colorectal adenocarcinoma and 
carcinoma cell lines 






AOM-induced colon carcinogenesis in 
mice 





AOM-induced colonic preneoplastic 
lesions in mice 
Reduced the number of ACF, BCAC, cell 
proliferation activity  
Increased apoptotic cells 
 
(30) 
100 and 500 
ppm, p.o. 
AOM/ DSS induced colon 
carcinogenesis in mice 
Suppressed the development of colonic 







tumorigenesis in rat 
Inhibited the development of esophageal 
tumors 
(32) 
0-50 µM, In 
vitro 
 
Human gastric carcinoma cell lines Suppressed CD74 expression, H. pylori 
adhesion and IL-8 production 
(33) 
100 and 500 
ppm, p.o. 
 
DEN-induced hepatocarcinogenesis in 
rat 





100 and 500 
ppm, p.o. 
DEN-induced hepatocarcinogenesis in 
rat 
Suppressed beta-catenin mutation (35) 
10 µM, In 
vitro 
Human breast cancer cell line Reduced cyclin D1 protein expression 
Inhibited IGF-1 stimulated S phase of cell 
cycle 
Modulated the transcription of many genes 
 
(9) 
0, 1 × 10-5, 5 
× 10-5, 1 × 
10- 4, 5 × 10- 












Prostate carcinogenesis using TRAP 






Reduced the epithelial component and high 
grade lesions in the lateral prostate lobe 
(10) 
100 and 500 
ppm, p.o. 
AOM-induced colon carcinogenesis in 
rat 
Reduced the incidence and multiplicity of 
colon adenocarcinoma, MDA and 4-HNE 
Suppressed ODC and polyamine content 






Experimental metastasis mouse 
model using B16BL6 melanoma cells 
Decreased the numbers of metastatic lung 
tumors, cross-sectional areas and volumes of 
the tumors  
Increased apoptotic indices 
 
(36) 
200 and 500 
ppm, p.o. 
MNU induced mammary carcinogenesis 
in rat 
Inhibited cell proliferation  




1–50 μM, In 
vitro 
 
200 and 500 
ppm, p.o. 
Human breast cancer cell line 
 
 
MNU induced mammary carcinogenesis 
in rat 
Suppressed proliferation  
Reduced IGF-1-induced cyclin D1 
expression 
Delayed median time to tumor  
Reduced cyclin D1 expression and 
incidence and multiplicity 
 
(38) 
100 and 500 
ppm, p.o. 
4-NQO-induced oral carcinogenesis Reduced the frequency and incidences of 
tongue carcinoma, BrdU-labelling index and 
polyamine  
Increased the activities of GST and QR 
 
(8) 
0, 15, 30, 
60, 90, and 
120 μM, In 
vitro 
Human prostate cancer cell line Increased TUNEL-positive cells, sub-G1 
population  
Cleaved poly (ADP-ribose) polymerase, 
activated pro-apoptotic protein Bax, caspase-
3 and caspase-9 Suppressed the expression 




0, 25, 50, 75 
and 100 µM, 
In vitro 
 
Human renal cancer cell line Inhibited glycolytic and mitochondrial 
metabolism, VEGF, and tube formation 
HUVECs 
(40) 





TPA-induced skin tumor Reduced tumor incidence and the numbers of 
tumors 
(17) 
10, 20, 40 
μg/ml, In 
vitro 
Cervical cancer,  breast cancer, 
oesophageal carcinoma and  T cell 
leukaemia cell lines 
Cytotoxic effect (41) 
Abbreviations: VEGF: vascular endothelial growth factor, HUVEC: human umbilical endothelial cells, 382 
AOM: azoxymethane, ACF: aberrant crypt foci, BCAC: ß-catenin-accumulated crypt, DSS: dextran sodium 383 
sulfate, NMBA: N-nitrosomethylbenzylamine, DEN: N,N-diethylnitrosamine, TRAP: transgenic rats 384 
developing adenocarcinoma of the prostate, MDA: malondialdehyde, 4-HNE: 4-hydroxy-2(E)-nonenal, 385 
ODC: ornithine decarboxylase activity, GST: glutathione S-transferase, QR: quinone reductase, MNU: N-386 
methylnitrosourea, IGF-1: insulin like growth factor1, 4-NQO:4-nitroquinoline 1-oxide, BrdU: 5-387 
bromodeoxyuridine, VEGF: vascular endothelial growth factor, TPA: 12-O-tetradecanoylphorbol-13-388 
acetate, p.o.: oral administration,  389 
 390 
Table 2. Summary of studies reporting neuroprotective effects of auraptene. 391 
Dose Exp. model Effect Ref. 
10 and 25 
mg/kg/day, 
s.c. 
2VO induced cerebral global ischemia 
in mice 
Reduced the numbers of IBA1-positive cells, 
GFAP-positive cells 
and COX-2-positive cells  
(43) 
25 and 50 
mg/kg, s.c. 
2VO induced cerebral global ischemia 
in mice 
Suppressed neuronal loss, microglia 






Healthy volunteers No effect on cognitive function (42) 
17 and 50 
mg/kg, i.p. 
Cuprizone-induced demyelination in 
mice 
Increased olig2 and the number OPCs 
Reduced the microglial activation 
 
(44) 
4, 8 and 25 
mg/kg, p.o. 
2VO induced cerebral global ischemia 
in rat 
Reduced the scape latency time  
Increased percentage time spent and traveled 
pathway in target quadrant 
 
(45) 
10, 30 and 
50 µM, In 
vitro 
 
Rat pheochromocytoma cell line Induced the activation of ERK1/2  
Promoted neurite outgrowth 
(46) 




memory retention  impairments in mice 
Reversed memory retention  impairments 




Abbreviations: 2VO: 2-vessel occlusion, IBA1: ionized calcium binding adaptor molecule 1, GFAP: glial 392 
fibrillary acidic protein, olig2: oligodendrocyte transcription factor 2, OPCs: oligodendrocyte lineage 393 
precursor cells, ERK: extracellular signal-regulated kinases,  394 
Table 3. Summary of studies reporting cardioprotective effects of auraptene. 395 
Dose Exp. model Effect Ref. 
5 and 50 
mg/kg, p.o. 
Myocardial infarction in rats Improved LVFS  








DOCA-induced hypertensive in rats Reduced MSBP  (49) 






Reduced MABP (50) 
0.6 ug/ml, In 
vitro 
Myocardial cells of rat Inhibited spontaneous beating of mouse 
myocardial cells 
(51) 
Abbreviations: LVFS: left ventricular fractional shortening, PWT: posterior wall thickness, DOCA: 396 
desoxycorticosterone acetate, MSBP: mean systolic blood pressure, MABP: mean arterial pressure, p.o.: 397 
oral administration, i.p.: intraperitoneal, i.v.: intravenous, 398 
 399 
Table 4. Summary of studies reporting immunomodulatory effects of auraptene.  400 
Dose Exp. model Effect Ref. 
10, 30 and 
90 µM, In 
vitro 
PHA-stimulated human lymphocytes Reduced IL-4, IL-10, IFN-γ, NF-κB and 
NO 
Increased IFN-γ/IL-4 and IL-10/IL-4 ratio 
 
(52) 
50, 100, 200 
and 400 
mM, In vitro 
 
H2O2-induced DNA toxicity in human 
lymphocytes 
Reduced  H2O2 genotoxicity (4) 
100, 200 or 
400 mg/kg, 
p.o. 
Peritoneal macrophages and splenic 
lymphocytes in mice 
Increased glucose consumption, activities of 
acid phosphatase and beta-glucuronidase and 
production of IL-1β and TNF-α  




0, 5, 10, 20 
and 40 µM, 
In vitro 
CD3/CD28-activated lymphocytes 
isolated from mice 
Inhibited CD3/CD28-activated lymphocyte 
proliferation  
Reduced IL-2, IFN-γ and IL-4 
(53) 
Abbreviations: PHA: phytohemagglutinin, H2O2: hydrogen peroxide. 401 
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Table 5. Summary of studies reporting protective effects of auraptene on gastrointestinal diseases. 402 
Dose Exp. model Effect Ref. 
7.5, 15 and 
30 mg/kg, 
p.o.   
LCA-induced cholestatic liver injury Increased bile acid efflux into intestine from 
liver  
Reduced hepatic uptake, liver inflammation, 
bile acid synthesis  
Increased bile acid metabolism 
  
(54) 
100 and 500 
ppm, p.o. 
AOM-induced colonic ACF in mice Reduced ACF frequency 
Reduced expression of cell proliferation 
indices 
Increased GST and QR activities 
 
(13) 
100 and 500 
ppm, p.o. 
H. pylori–infected mice Inhibited gastric mucousal injuries due to H. 
pylori colonisation 
Attenuated expressions of CD74, IL-1β, 
TNF-α, and level MIP-2 
 
(55) 
0.5 and 1 
g/kg, oral. 
OLETF rats Reduced abdominal white adipose tissue 
weight and TG 
Increased carnitine acyl-CoA oxidase, 
palmitoyltransferase and peroxisomal ß-
oxidation 
(56) 
1-100 µM, In 
vitro 
Human hepatocarcinoma cell line Increased PPARα and PPARγ levels  
Increased mRNA expression of adiponectin 
in 3T3-L1 adipocytes and adiponectin 
secretion  
(57) 




5, 10 and 20 
µM, In vitro 
 




Inhibited activation of HSCs 
Reduced expression of TNF-α, IL-1β, NF-
κB 
 
Increased cell viability 
(58) 
100 and 500 
ppm, p.o. 





DSS-induced ulcerative colitis in mice Suppressed gelatinolytic activity of MMP-7 
as well as MMP-2 and -9 expression 
(60) 
Abbreviations: LCA: lithocholic acid, AOM: azoxymethane, ACF: aberrant crypt foci, MIP-2: macrophage 403 
inhibitory protein-2, TG: hepatic triglyceride, OLETF: Otsuka Long-Evans Tokushima fatty, TAA: 404 





Table 6. Summary of studies reporting miscellaneous effects of auraptene. 408 
Dose Exp. model Effect Ref. 
0.1 and 0.2%, 
p.o. 
HFD-fed KK-Ay obese diabetic mice Suppressed lipid accumulation 
Inhibited enhancement in plasma glucose 
and insulin levels 






STZ-induced diabetes in mice Suppressed astroglial activation and 
neuronal hyper phosphorylation of tau at 231 
of threonine  
Reversed suppression of neurogenesis in 
hippocampal dentate gyrus 
 
(61) 
0, 12.5, 25, 




LPS-stimulated human macrophages Inhibits P. gingivalis adherence to oral 
epithelial cells  
Reduced TNF-α, IL-8, MMP 
(62) 
0, 0.2, 1, 5, 




LPS-stimulated epithelial cells from 
oral cavity 
Reduced secretion of chemokine (C-C motif) 
ligand (CCL)-5, IL-6, IL-8, MMP-2 
(63) 
200, 250, 
300 µM, In 
vitro 
 
Murine macrophage cell line Reduced PGE2 production, mRNA 
expression and COX-2 protein 
(5) 
5, 10 and 20 
µM, In vitro 
Murine macrophage cell line Suppressed the expression of MCP-1, COX-









Leishmania major cells 
 
Inhibited growth of L. major promastigotes 
 
(3) 
Abbreviations: HFD: high-fat-diet, STZ: streptozotocin, P. gingivalis: Porphyromonas gingivalis, 409 
MMP: matrix metalloproteinase, LPS: lipopolysaccharide, CCL-5: chemokine (C-C motif) ligand-410 
5, TNF-α: tumor necrosis factor, PGE2: prostaglandin E2, COX-2: cyclooxygenase-2, iNOS:  411 
inducible nitric oxide synthase, MCP-1: monocyte chemoattractant protein-1, L. major: 412 
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